Propofol protects H9C2 cells against hypoxia/reoxygenation injury through miR‑449a and NR4A2
Affiliations: Department of Anesthesiology, Children's Hospital of Soochow University, Suzhou, Jiangsu 215000, P.R. China
- Published online on: August 16, 2021 https://doi.org/10.3892/etm.2021.10615
Copyright: © Qian
et al. This is an open access article distributed under the
terms of Creative
Commons Attribution License.
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Propofol has been revealed to protect cardiomyocytes against myocardial ischemia injury, although the underlying mechanism remains incompletely understood. H9C2 cells were used to generate a hypoxia/reoxygenation (H/R) in vitro model for the present study. Reverse transcription‑quantitative PCR and western blotting were performed to measure the expression levels of microRNA (miR)‑449a and nuclear receptor subfamily 4 group A member 2 (NR4A2). The CCK‑8, BrdU, EdU, and caspase‑3 activity assays and western blot analysis were employed to detect cell viability, proliferation, and apoptosis. The target relationship between miR‑449a and NR4A2 was verified through dual‑luciferase reporter assays. The results confirmed that exposure of the cells to H/R resulted in severe cell injury. However, the presence of propofol improved cell activity by promoting cell viability and proliferation and inhibiting cell apoptosis. The beneficial effect of propofol on H/R‑mediated injury could be abrogated by the inhibition of NR4A2 mediated by miR‑449a. Thus, the present study demonstrated that propofol counteracted cardiomyocyte H/R injury by inhibiting miR‑449a to upregulate NR4A2.